The
Item 7.01 Regulation FD Disclosure. On October 3, 2022, Illumina, Inc. hosted an Investor Day event, including a live webcast presentation and Q&A session. During the event, the current number... | October 6, 2022
Customized tools for collaborating in the clouds allow scientists to take back their time.
Illumina’s partners say they believe the company will continue to improve the speed and continue to lower the price. San Diego-based Illumina, Inc., has launched a “production scale” sequencer that it claims can process human genomes in half a day for $200.
With a divestiture order from the European Commission looming, Illumina is looking at strategic options for the maker of blood tests used to detect cancer.
Shares of Illumina Inc. advanced 9.52% to $205.06 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...
A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 26 strange trades.
Korea is utilizing only a fraction of the potential of next generation sequencing (NGS) and has yet to recognize the full value of the platform, Illumina’s sales head for the Asia region said.“Korea should make efforts to let the public know the cost-effectiveness of NGS in reducing medical costs,”
September jobs numbers will be released on Friday, plus earnings from Lamb Weston, Conagra, McCormick, and Constellation. Also, September PMIs and August JOLTS.
Last week, GenomeWeb’s readers were most interested in Illumina’s announcement of the new NovaSeq X series sequencers.
???????? ?? ??? ?????? – A new study titled Digital Genome Market 2022, published by The Coherent Market Insights, provides information on regional and
Illumina has introduced what it calls its fastest and most efficient sequencing machines, the NovaSeq X series.
Gun jumping: recent developments and practices to be avoided - A few recent decisions of the French and European competition...
The DNA sequencing giant generated over 10% of its diluted earnings per share in 2021 from a tax holiday.
Sequencing behemoth Illumina unveiled a new line of instruments today.
Shares of Illumina Inc. shed 3.72% to $193.81 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...
Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.
In a report currently being published by Verified Market Research titled “Global Biomarker Tech
″ Get Sample Report Buy Complete Report Gene Expression Analysis Market research is an intelli